Small-molecule BCR-ABL1 tyrosine kinase inhibitors (TKIs) have fundamentally improved the treatment of chronic myeloid leukaemia (CML) and have become a paradigm for molecularly targeted therapy, but ...
Novartis AG’s financial update included good news about Scemblix (asciminib), the first and only U.S. FDA-approved allosteric inhibitor for chronic myeloid leukemia (CML), which gained clearance in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback